Effects of simvastatin on apolipoprotein M in vivo and in vitro
Open Access
- 5 July 2011
- journal article
- research article
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 10 (1) , 112
Abstract
Objective: To investigate effects of lipid lowering drug, simvastatin, on apolipoprotein M expression in the hyperlipidemic mice and in hepatic cell line, HepG2 cells. Methods: Swiss male mice were randomly divided into the high fat group and control group, and were intragastrically fed with 0.9% saline (control group) or lipid emulsion (high fat group) at the daily dosage of 15 ml/kg body weight, respectively. After 8 weeks feeding, the hyperlipidemic model was successfully induced and these hyperlipidemic mice were then randomly divided into three experimental groups: vehicle control group, high-dose simvastatin-treated group (100 mg/kg body weight), and low-dose simvastatin-treated group (10 mg/kg body weight). Mice were dosed daily for 6 weeks of simvastatin before mice were sacrificed for determining serum lipid profile and apoM protein levels that was determined by using dot blotting analysis. Effects of simvastatin on apoM mRNA expression in the HepG2 cells were determined by real-time RT-PCR. Results: Comparing to high fat model mice without simvastatin treatment, 100 mg/kg simvastatin could significantly increase serum total cholesterol (P < 0.05). Serum apoM levels, in all mice, were significantly lower in the mice at the age of 26 weeks than the mice at 12 weeks old (P < 0.05), which indicated that serum apoM levels were significantly correlated to the mice age. It demonstrated also that treatment of simvastatin did not influence serum apoM levels in these mouse model, although serum apoM levels were increased by about 13% in the 10 mg/kg simvastatin group than in the vehicle control group without simvastatin. In HepG2 cell cultures, simvastatin could significantly decrease apoM mRNA levels with dose- and time-dependent manners. At 10 μM simvastatin treatment, apoM mRNA decreased by 52% compared to the controls. Conclusion: The present study suggested that simvastatin, in vivo, had no effect on apoM levels in the hyperlipidemic mouse model. ApoM serum levels in mice were significantly correlated to the animal's age, whereas in cell cultures simvastatin does inhibit apoM expression in the HepG2 cells. The mechanism behind it is not known yet.Keywords
This publication has 22 references indexed in Scilit:
- Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein MProceedings of the National Academy of Sciences, 2011
- Foxa2 Activity Increases Plasma High Density Lipoprotein Levels by Regulating Apolipoprotein MJournal of Biological Chemistry, 2008
- Liver Receptor Homolog 1 Is a Negative Regulator of the Hepatic Acute-Phase ResponseMolecular and Cellular Biology, 2006
- Diet and Murine AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- Characterization of apoM in normal and genetically modified miceJournal of Lipid Research, 2004
- Transforming growth factor-beta down-regulates apolipoprotein M in HepG2 cellsBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2004
- Simvastatin, an HMG-CoA reductase inhibitor, induces the synthesis and secretion of apolipoprotein AI in HepG2 cells and primary hamster hepatocytesAtherosclerosis, 2002
- Anti-atherosclerotic effect of simvastatin depends on the presence of apolipoprotein EAtherosclerosis, 2002
- Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)The Lancet, 1994
- The effect of the HMG-CoA reductase inhibitor simvastatin and of cholestyramine on hepatic apolipoprotein mRNA levels in the ratBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1993